.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Merck
McKinsey
Dow
Harvard Business School
Johnson and Johnson
Queensland Health
Mallinckrodt
Colorcon
Healthtrust

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,637,079

« Back to Dashboard

Which drugs does patent 8,637,079 protect, and when does it expire?


Patent 8,637,079 protects OSENI and is included in one NDA.

This patent has thirty-eight patent family members in thirty-six countries.

Summary for Patent: 8,637,079

Title:Solid preparation comprising alogliptin and pioglitazone
Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
Inventor(s): Nakamura; Kenji (Osaka, JP), Kiyoshima; Kenichiro (Osaka, JP), Nomura; Junya (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/449,255
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-004Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-003Jan 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,637,079

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-023594Feb 1, 2007
PCT Information
PCT FiledJanuary 30, 2008PCT Application Number:PCT/JP2008/051900
PCT Publication Date:August 07, 2008PCT Publication Number: WO2008/093882

International Patent Family for Patent: 8,637,079

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Chile2008000279► Subscribe
China101646420► Subscribe
Costa Rica10992► Subscribe
Cyprus1111264► Subscribe
Germany602008003522► Subscribe
Denmark2107905► Subscribe
Dominican RepublicP2009000195► Subscribe
Eurasian Patent Organization200970726► Subscribe
Eurasian Patent Organization015180► Subscribe
EcuadorSP099608► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
US Department of Justice
Boehringer Ingelheim
McKinsey
Chubb
Accenture
Cerilliant
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot